SCHEMBL283720

SCHEMBL283720

[CH2]C1CCCC2CCCCC12

nearest known ligand 0.39

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1289723 0.97 ALDH1A1 (0.41) ALDH1A1
SCHEMBL6590771 0.97 ALDH1A1 (0.33) ALDH1A1
SCHEMBL6585886 0.88 ALDH1A1 (0.39) ALDH1A1
SCHEMBL6592037 0.88
SCHEMBL16909193 0.77 ALDH1A1 (0.54) ALDH1A1
SCHEMBL11265164 0.77 ALDH1A1 (0.54) ALDH1A1
SCHEMBL6590050 0.77
SCHEMBL9949155 0.76 ALDH1A1 (0.33) ALDH1A1
SCHEMBL11848572 0.74 ALDH1A1 (0.50) ALDH1A1
SCHEMBL1305825 0.74 ALDH1A1 (0.50) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0916668-A1 CHEMOKINE RECEPTOR ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 1999-05-19 EP claimed
EP-0435059-B1 Retroviral protease inhibitors HOECHST AG (DE) 1997-11-05 EP claimed
US-5663139-A VIRICIDE OLIGOPEPTIDES HOECHST AKTIENGESELLSCHAFT (DE) 1997-09-02 US claimed
EP-0688314-A1 PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1995-12-27 EP claimed
EP-0649426-A1 INHIBITORS OF RETROVIRAL PROTEASES HOECHST AKTIENGESELLSCHAFT (DE) 1995-04-26 EP claimed
WO-1994021604-A1 PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1994-09-29 WO claimed
WO-1994000461-A1 INHIBITORS OF RETROVIRAL PROTEASES HOECHST AKTIENGESELLSCHAFT (DE) 1994-01-06 WO claimed
EP-0435059-A1 Retroviral protease inhibitors HOECHST AKTIENGESELLSCHAFT (DE) 1991-07-03 EP claimed
EP-0428849-A2 Retroviral protease inhibitors HOECHST AKTIENGESELLSCHAFT (DE) 1991-05-29 EP claimed
CN-1050545-A Inhibitors of post-infective viral proteases HOECHST AG (DE) 1991-04-10 CN claimed
US-RE31342-E STABILIZERS FOR POLYMERS CIBA-GEIGY CORPORATION (US) 1983-08-09 US claimed
CN-117510500-A Preparation method of asperazepanones alkaloid and application of asperazepanones alkaloid as anti-inflammatory drug 中国海洋大学 2024-02-06 CN disclosed
CN-116726010-A Application of macrolide derivative in preparation of medicines for inhibiting pro-inflammatory cytokine acting agents 中国海洋大学 2023-09-12 CN disclosed
US-20230064214-A1 TREATMENT AND PROGNOSIS OF PANCREATIC CANCER CAMBRIDGE ENTERPRISE LIMITED (GB) 2023-03-02 US disclosed
CN-112851622-B Macrolide brefeldin A ester derivative and application thereof 中国海洋大学 2023-01-10 CN disclosed
WO-1994000461-A1 INHIBITORS OF RETROVIRAL PROTEASES HOECHST AKTIENGESELLSCHAFT (DE) 1994-01-06 WO disclosed
EP-0435059-A1 Retroviral protease inhibitors HOECHST AKTIENGESELLSCHAFT (DE) 1991-07-03 EP disclosed
US-5025048-A Oxygen resistant, storage-stable curable polysiloxanes hydrosilated by a polycyclic polyene and a compound containing an amine and a hydroxy, both sterically hindered HERCULES INCORPORATED (US) 1991-06-18 US disclosed
EP-0428849-A2 Retroviral protease inhibitors HOECHST AKTIENGESELLSCHAFT (DE) 1991-05-29 EP disclosed
CN-1050545-A Inhibitors of post-infective viral proteases HOECHST AG (DE) 1991-04-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230064214-A1 TREATMENT AND PROGNOSIS OF PANCREATIC CANCER PDCD1, CCR1, CD274 ALDH1A1 1292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.